Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW,...
Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW,...
Distribution network coverage expanded to a total of 39 countriesGARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air,...
Distribution network coverage expanded to a total of 39 countriesGARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air,...
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients,...
A Defining Year Positioning Predictmedix AI at the Convergence of Quantum, AI, and HealthcareToronto, Ontario--(Newsfile Corp. - December 17, 2025)...
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers...
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial...
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14,...
Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum...
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months...
Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard...
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment...
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or...
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...